Availability of Two Draft Toxicological Profiles, 3662-3663 [2024-01007]
Download as PDF
3662
Federal Register / Vol. 89, No. 13 / Friday, January 19, 2024 / Notices
Rule requirements and the basis for the
calculations summarized below, see 88
FR 59923.
Your comment—including your name
and your state—will be placed on the
public record of this proceeding.
Because your comment will be made
public, you are solely responsible for
making sure that your comment does
not include any sensitive personal
information, such as anyone’s Social
Security number; date of birth; driver’s
license number or other state
identification number or foreign country
equivalent; passport number; financial
account number; or credit or debit card
number. You are also solely responsible
for ensuring that your comment does
not include any sensitive health
information, such as medical records or
other individually identifiable health
information. In addition, your comment
should not include any ‘‘[t]rade secret or
any commercial or financial information
which is . . . privileged or
confidential’’—as provided in Section
6(f) of the FTC Act 15 U.S.C. 46(f), and
FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—
including, in particular, competitively
sensitive information, such as costs,
sales statistics, inventories, formulas,
patterns devices, manufacturing
processes, or customer names.
Josephine Liu,
Assistant General Counsel for Legal Counsel.
[FR Doc. 2024–01004 Filed 1–18–24; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[Docket No. ATSDR–2023–0005]
Availability of Two Draft Toxicological
Profiles
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Agency for Toxic
Substances and Disease Registry
(ATSDR), within the Department of
Health and Human Services (HHS),
announces the opening of a docket to
obtain comments on drafts of two
updated toxicological profiles:
chloroform and chloroethane. This
action is necessary as this is the
opportunity for members of the public
and organizations to submit comments
on drafts of the profiles. The intended
effect of this action is to ensure that the
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:42 Jan 18, 2024
Jkt 262001
public can note any pertinent additional
information or reports on studies about
the health effects caused by exposure to
the substances covered in these two
profiles for review.
DATES: Written comments must be
received on or before April 18, 2024.
ADDRESSES: You may submit comments,
identified by Docket No. ATSDR–2023–
0005 by either of the methods listed
below. Do not submit comments by
email. ATSDR does not accept
comments by email.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Agency for Toxic Substances
and Disease Registry, Office of
Innovation and Analytics, 4770 Buford
Highway, Mail Stop S106–5, Atlanta,
GA 30341–3717. Attn: Docket No.
ATSDR–2023–0005.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Farhana Rahman, Agency for Toxic
Substances and Disease Registry, Office
of Innovation and Analytics, 4770
Buford Highway, Mail Stop S106–5,
Atlanta, GA 30329–4027; Email:
ATSDRToxProfileFRNs@cdc.gov; Phone:
1–800–232–4636.
SUPPLEMENTARY INFORMATION: ATSDR
has prepared drafts of two updated
toxicological profiles based on current
understanding of the health effects and
availability of new studies and other
information since their initial release.
All toxicological profiles issued as
‘‘Drafts for Public Comment’’ represent
the result of ATSDR’s evidence-based
evaluations of the available literature to
provide important toxicological
information on priority hazardous
substances to the public and health
professionals. ATSDR considers key
studies for these substances during the
profile development process, using a
systematic review approach. To that
end, ATSDR is seeking public
comments and additional information or
reports on studies about the health
effects of these substances for review
and potential inclusion in the profiles.
ATSDR will evaluate the quality and
relevance of such data or studies for
possible inclusion in the profile.
Legislative Background
The Superfund Amendments and
Reauthorization Act of 1986 (SARA) [42
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
U.S.C. 9601 et seq.] amended the
Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA or Superfund) [42
U.S.C. 9601 et seq.] by establishing
certain requirements for ATSDR and the
U.S. Environmental Protection Agency
(EPA) regarding the hazardous
substances most commonly found at
facilities on the CERCLA National
Priorities List. Among these statutory
requirements is a mandate for the
Administrator of ATSDR to prepare
toxicological profiles for each substance
included on the priority list of
hazardous substances [also called the
Substance Priority List (SPL)]. This list
identifies 275 hazardous substances that
ATSDR has determined pose the most
significant potential threat to human
health. The SPL is available online at
https://www.atsdr.cdc.gov/SPL. ATSDR
is also mandated to revise and publish
updated toxicological profiles, as
necessary, to reflect updated health
effects and other information.
In addition, CERCLA provides ATSDR
with the authority to prepare
toxicological profiles for substances not
found on the SPL. CERCLA authorizes
ATSDR to establish and maintain an
inventory of literature, research, and
studies on the health effects of toxic
substances (CERCLA Section
104(i)(1)(B); 42 U.S.C. 9604(i)(1)(B)); to
respond to requests for health
consultations (CERCLA Section
104(i)(4); 42 U.S.C. 9604(i)(4)); and to
support the site-specific response
actions conducted by the agency
(CERCLA Section 104(i)(6); 42 U.S.C.
9604(i)(6)).
ATSDR has now prepared drafts of
two updated toxicological profiles based
on current understanding of the health
effects and availability of new studies
and other information since their initial
release.
Availability
The draft toxicological profiles and
interaction profile are available online
at https://www.regulations.gov, Docket
No. ATSDR–2023–0005 and at https://
www.atsdr.cdc.gov/ToxProfiles.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
E:\FR\FM\19JAN1.SGM
19JAN1
Federal Register / Vol. 89, No. 13 / Friday, January 19, 2024 / Notices
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
ATSDR will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. Do not submit comments by
email. ATSDR does not accept
comments by email.
Donata Green,
Associate Director, Office of Policy, Planning
and Partnerships, Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2024–01007 Filed 1–18–24; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2024–0003]
Meeting of the Advisory Committee to
the Director, Centers for Disease
Control and Prevention
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting for the Advisory
Committee to the Director, Centers for
Disease Control and Prevention (ACD,
CDC). This is a hybrid meeting,
accessible both in person and virtually
(webcast live via the World Wide Web).
It is open to the public and limited only
by the space available. Time will be
available for public comment.
DATES: The meeting will be held on
February 21, 2024, from 9 a.m. to 3 p.m.,
EST (times subject to change).
Written comments must be received
on or before February 5, 2024.
ADDRESSES: Meeting address: CDC
Roybal Campus, Building 21, Room
1204 A/B, 1600 Clifton Road NE,
Atlanta, Georgia 30329–4027.
Please note that the meeting location,
the CDC Roybal Campus, is a federal
facility and in-person access is limited
to United States citizens unless prior
authorizations, taking up to 30 to 60
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:42 Jan 18, 2024
Jkt 262001
days, have been made. Visitors must
follow all directions for access to CDC
facilities. Directions for visitors to CDC,
including safety requirements related to
COVID–19; are available at https://
www.cdc.gov/screening/visitors.html.
Registration: You must register to
attend this meeting in person. If you
wish to attend in person, please submit
a request by email to ACDirector@
cdc.gov at least 5 business days in
advance of the meeting. No registration
is required to view the meeting via the
World Wide Web. Information for
accessing the webcast will be available
at https://www.cdc.gov/about/advisorycommittee-director/.
Written comments: You may submit
comments, identified by Docket No.
CDC–2024–0003, by either of the
following methods below. Do not
submit comments for the docket by
email. CDC does not accept comments
for the docket by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Kerry Caudwell, DPA, Centers
for Disease Control and Prevention,
1600 Clifton Road NE, Mailstop H21–10,
Atlanta, Georgia 30329–4027. Attn:
Docket number CDC–2024–0003.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received will be posted without change
to https://www.regulations.gov,
including any personal information
provided. For access to the docket to
read background documents or
comments received, go to https://
www.regulations.gov. Written comments
received in advance of the meeting will
be included in the official record of the
meeting.
FOR FURTHER INFORMATION CONTACT:
Kerry Caudwell, D.P.A., Office of the
Chief of Staff, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop H21–10, Atlanta,
Georgia 30329–4027, Telephone: (404)
639–0390; Email Address: ACDirector@
cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee to
the Director, CDC, shall (1) make
recommendations to the Director
regarding ways to prioritize the
activities of the agency in alignment
with the CDC Strategic Plan required
under section 305(c); H.R. 2617–1252;
(2) advise on ways to achieve or
improve performance metrics in relation
to the CDC Strategic Plan, and other
relevant metrics, as appropriate; (3)
provide advice and recommendations
on the development of the Strategic
Plan, and any subsequent updates, as
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
3663
appropriate; (4) advise on grant,
cooperative agreements, contracts, or
other transactions, as applicable; (5)
provide other advice to the Director, as
requested, to fulfill duties under
sections 301 and 311; and (6) appoint
subcommittees. The committee
recommends ways to prioritize CDC’s
activities, improve results, and address
health disparities. It also provides
guidance to help CDC work more
effectively with its various private and
public sector constituents to make
health protection a practical reality.
Matters to be Considered: The agenda
includes updates on CDC programs,
Director’s focus areas, and the Moving
Forward Initiative. Agenda items are
subject to change as priorities dictate.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on January 19, 2024 through
February 5, 2024.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
E:\FR\FM\19JAN1.SGM
19JAN1
Agencies
[Federal Register Volume 89, Number 13 (Friday, January 19, 2024)]
[Notices]
[Pages 3662-3663]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01007]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
[Docket No. ATSDR-2023-0005]
Availability of Two Draft Toxicological Profiles
AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR),
Department of Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR),
within the Department of Health and Human Services (HHS), announces the
opening of a docket to obtain comments on drafts of two updated
toxicological profiles: chloroform and chloroethane. This action is
necessary as this is the opportunity for members of the public and
organizations to submit comments on drafts of the profiles. The
intended effect of this action is to ensure that the public can note
any pertinent additional information or reports on studies about the
health effects caused by exposure to the substances covered in these
two profiles for review.
DATES: Written comments must be received on or before April 18, 2024.
ADDRESSES: You may submit comments, identified by Docket No. ATSDR-
2023-0005 by either of the methods listed below. Do not submit comments
by email. ATSDR does not accept comments by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Agency for Toxic Substances and Disease Registry,
Office of Innovation and Analytics, 4770 Buford Highway, Mail Stop
S106-5, Atlanta, GA 30341-3717. Attn: Docket No. ATSDR-2023-0005.
Instructions: All submissions received must include the agency name
and Docket Number. All relevant comments received will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Farhana Rahman, Agency for Toxic
Substances and Disease Registry, Office of Innovation and Analytics,
4770 Buford Highway, Mail Stop S106-5, Atlanta, GA 30329-4027; Email:
[email protected]; Phone: 1-800-232-4636.
SUPPLEMENTARY INFORMATION: ATSDR has prepared drafts of two updated
toxicological profiles based on current understanding of the health
effects and availability of new studies and other information since
their initial release. All toxicological profiles issued as ``Drafts
for Public Comment'' represent the result of ATSDR's evidence-based
evaluations of the available literature to provide important
toxicological information on priority hazardous substances to the
public and health professionals. ATSDR considers key studies for these
substances during the profile development process, using a systematic
review approach. To that end, ATSDR is seeking public comments and
additional information or reports on studies about the health effects
of these substances for review and potential inclusion in the profiles.
ATSDR will evaluate the quality and relevance of such data or studies
for possible inclusion in the profile.
Legislative Background
The Superfund Amendments and Reauthorization Act of 1986 (SARA) [42
U.S.C. 9601 et seq.] amended the Comprehensive Environmental Response,
Compensation, and Liability Act of 1980 (CERCLA or Superfund) [42
U.S.C. 9601 et seq.] by establishing certain requirements for ATSDR and
the U.S. Environmental Protection Agency (EPA) regarding the hazardous
substances most commonly found at facilities on the CERCLA National
Priorities List. Among these statutory requirements is a mandate for
the Administrator of ATSDR to prepare toxicological profiles for each
substance included on the priority list of hazardous substances [also
called the Substance Priority List (SPL)]. This list identifies 275
hazardous substances that ATSDR has determined pose the most
significant potential threat to human health. The SPL is available
online at https://www.atsdr.cdc.gov/SPL. ATSDR is also mandated to
revise and publish updated toxicological profiles, as necessary, to
reflect updated health effects and other information.
In addition, CERCLA provides ATSDR with the authority to prepare
toxicological profiles for substances not found on the SPL. CERCLA
authorizes ATSDR to establish and maintain an inventory of literature,
research, and studies on the health effects of toxic substances (CERCLA
Section 104(i)(1)(B); 42 U.S.C. 9604(i)(1)(B)); to respond to requests
for health consultations (CERCLA Section 104(i)(4); 42 U.S.C.
9604(i)(4)); and to support the site-specific response actions
conducted by the agency (CERCLA Section 104(i)(6); 42 U.S.C.
9604(i)(6)).
ATSDR has now prepared drafts of two updated toxicological profiles
based on current understanding of the health effects and availability
of new studies and other information since their initial release.
Availability
The draft toxicological profiles and interaction profile are
available online at https://www.regulations.gov, Docket No. ATSDR-2023-
0005 and at https://www.atsdr.cdc.gov/ToxProfiles.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider
[[Page 3663]]
confidential or inappropriate for public disclosure. If you include
your name, contact information, or other information that identifies
you in the body of your comments, that information will be on public
display. ATSDR will review all submissions and may choose to redact, or
withhold, submissions containing private or proprietary information
such as Social Security numbers, medical information, inappropriate
language, or duplicate/near duplicate examples of a mass-mail campaign.
Do not submit comments by email. ATSDR does not accept comments by
email.
Donata Green,
Associate Director, Office of Policy, Planning and Partnerships, Agency
for Toxic Substances and Disease Registry.
[FR Doc. 2024-01007 Filed 1-18-24; 8:45 am]
BILLING CODE 4163-70-P